The United Kingdom and the United States have concluded a important bilateral deal that will guarantee no levies on UK medicine shipments being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the National Health Service (NHS). This pledge guarantees that duties on these key exports will be held at nothing for a timeframe of the next three years.
This deal comes after earlier threats to significantly raise duties on branded pharmaceutical imports, with potential rates floated reaching 100%.
"This arrangement between the Britain strengthens the global environment for new treatments and introduces much-needed balance to American-British drug exports," an announcement said.
Trade Significance
Pharmaceuticals constitute one of the Britain's largest export categories to the United States, which is by far the biggest buyer for leading UK drugmakers.
Export figures reveal that in the 12 months prior to the third quarter, the UK sold medicines totaling £11.1bn to the US. This amount accounted for a significant portion of British export trade in that period.
"This agreement protects jobs, boosts investment and paves the way for the UK to become a international leader for life sciences," a minister stated.
Key NHS Changes
The deal entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a target to double overall public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds were more than 20%.
Broader Context
The deal follows a ongoing row between the pharmaceutical industry and the UK government over spending levels and regulatory access.
The disagreement were heightened by assertions that American patients were paying several times more for the equivalent treatments than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the past decade.
